Healthesystems is attending the Ohio Bureau of Workers’ Compensation Safety Congress & Expo, the nation’s largest free occupational safety conference focusing on helping employers improve safety and health within their business.
Healthesystems is attending and sponsoring the Kids’ Chance National Conference, a national gathering of the Kids’ Chance community.
Approval Date: Jul 2025
Indicated for the treatment of hypertension to lower blood pressure, in patients 55 and older to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, and in patients with post-myocardial infarction heart failure to reduce risk of death and hospitalization
Approval Date: Jul 2025
Indicated to improve glycemic control in patients with diabetes mellitus
Approval Date: Jun 2025
Indicated as an adjunct to diet and exercise to improve glycemic control for the treatment of type 2 diabetes
Approval Date: Jun 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns
Approval Date: May 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns. In March, a 2.5 mg dose of this generic was approved; this approval applies to 10 mg, 15 mg, and 20 mg doses
Approval Date: May 2025
Indicated as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy.
Approval Date: May 2025
While DHE has been available since 1946, this is the first DHE drug available in a ready-to-use autoinjector, indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches
Approval Date: May 2025
Indicated for the treatment of pulmonary arterial hypertension, this is the first and only dry-powder formulation of treprostinil
Approval Date: May 2025
A biosimilar to Stelara (ustekinumab), this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severely active Crohn’s disease, and moderate to severely active Ulcerative Colitis
Approval Date: Apr 2025
While DHE has been available since 1946, this is the first DHE drug available in a nasal powder formulation and indicated for the acute treatment of migraine with or without aura
Approval Date: Mar 2025
Indicated for the treatment of hypertension, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic neuropathy in certain type 2 diabetes patients with hypertension
Approval Date: Mar 2025
A biosimilar to Acterma®, this autoimmune drug has received an additional indication for the treatment of COVID-19 in hospitalized patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
Approval Date: Jan 2025
A combination NSAID and triptan drug indicated for the acute treatment of migraine with or without aura
Approval Date: Jan 2025
An NMDA receptor antagonist, this drug is now indicated for use as a monotherapy for treatment-resistant depression (TRD). Spravato originally required conjunctive use with an oral antidepressant for (TRD)
Approval Date: Jan 2025
A biosimilar to Acterma, this drug is indicated for rheumatoid arthritis, giant cell arteritis, and COVID-19 in hospitalized patients receiving supplemental oxygen and corticosteroids, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
